Editorial: A Novel Monoclonal Antibody-Targeting Angiogenesis by Inhibiting Secreted Frizzled-Related Protein 2

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2019 Sep 11

PMID 31502016

Authors

Julie E Lang

William W Tseng

Irene Kang

Affiliations

Soon will be listed here.

References

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E . Synergy between tumor immunotherapy and antiangiogenic therapy. Blood. 2003; 102(3):964-71. DOI: 10.1182/blood-2002-12-3738. View

Courtwright A, Siamakpour-Reihani S, Arbiser J, Banet N, Hilliard E, Fried L . Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res. 2009; 69(11):4621-8. PMC: 2699405. DOI: 10.1158/0008-5472.CAN-08-3402. View

Khan K, Kerbel R . Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018; 15(5):310-324. DOI: 10.1038/nrclinonc.2018.9. View

Cook K, Figg W . Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010; 60(4):222-43. PMC: 2919227. DOI: 10.3322/caac.20075. View

Al-Abd A, Alamoudi A, Abdel-Naim A, Neamatallah T, Ashour O . Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. J Adv Res. 2017; 8(6):591-605. PMC: 5544473. DOI: 10.1016/j.jare.2017.06.006. View

Jin Y, Chauhan S, El Annan J, Annan J, Sage P, Sharpe A . A novel function for programmed death ligand-1 regulation of angiogenesis. Am J Pathol. 2011; 178(4):1922-9. PMC: 3078456. DOI: 10.1016/j.ajpath.2010.12.027. View

Chen H, Cleck J . Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009; 6(8):465-77. DOI: 10.1038/nrclinonc.2009.94. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

10.

Vasudev N, Reynolds A . Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014; 17(3):471-94. PMC: 4061466. DOI: 10.1007/s10456-014-9420-y. View

11.

Crago A, Chmielecki J, Rosenberg M, OConnor R, Byrne C, Wilder F . Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015; 54(10):606-15. PMC: 4548882. DOI: 10.1002/gcc.22272. View

12.

Lode H, Moehler T, Xiang R, Jonczyk A, Gillies S, Cheresh D . Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci U S A. 1999; 96(4):1591-6. PMC: 15528. DOI: 10.1073/pnas.96.4.1591. View

13.

Cironi L, Petricevic T, Fernandes Vieira V, Provero P, Fusco C, Cornaz S . The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma. Sci Rep. 2016; 6:22113. PMC: 4764983. DOI: 10.1038/srep22113. View

14.

Ramjiawan R, Griffioen A, Duda D . Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. Angiogenesis. 2017; 20(2):185-204. PMC: 5439974. DOI: 10.1007/s10456-017-9552-y. View

15.

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View

16.

Uluckan O, Segaliny A, Botter S, Santiago J, Mutsaers A . Preclinical mouse models of osteosarcoma. Bonekey Rep. 2015; 4:670. PMC: 4422092. DOI: 10.1038/bonekey.2015.37. View

17.

Reidy D, Chung K, Timoney J, Park V, Hollywood E, Sklarin N . Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007; 25(19):2691-5. DOI: 10.1200/JCO.2006.09.3351. View

18.

Maroulakou I, Anver M, Garrett L, Green J . Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci U S A. 1994; 91(23):11236-40. PMC: 45202. DOI: 10.1073/pnas.91.23.11236. View

19.

Motz G, Coukos G . The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011; 11(10):702-11. DOI: 10.1038/nri3064. View

20.

Vijayakumar S, Liu G, Rus I, Yao S, Chen Y, Akiri G . High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell. 2011; 19(5):601-12. PMC: 3116447. DOI: 10.1016/j.ccr.2011.03.010. View